HC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)

HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $37.00 price objective on the stock.

Separately, Jefferies Financial Group assumed coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock.

Pharming Group Trading Up 0.3 %

NASDAQ:PHAR opened at $8.77 on Friday. Pharming Group has a one year low of $6.65 and a one year high of $11.80. The business has a fifty day moving average price of $8.99 and a 200-day moving average price of $8.58. The firm has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Sell-side analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.